Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Illumina Yönetim

Yönetim kriter kontrolleri 3/4

Illumina's CEO'su Jacob Thaysen, Sep2023 tarihinde atandı, in görev süresi 1.08 yıldır. in toplam yıllık tazminatı $ 4.69M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.3% maaş ve 94.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.005% ine doğrudan sahiptir ve bu hisseler $ 955.62K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 6.3 yıldır.

Anahtar bilgiler

Jacob Thaysen

İcra Kurulu Başkanı

US$4.7m

Toplam tazminat

CEO maaş yüzdesi	5.3%
CEO görev süresi	1.1yrs
CEO sahipliği	0.005%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	6.3yrs

Son yönetim güncellemeleri

Recent updates

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Aug 21

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Jul 01

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22

The Big Trends: New Frontiers in Healthcare

Jul 13

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14

Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?

Dec 30

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?

Dec 02

CEO Tazminat Analizi

Jacob Thaysen'un ücretlendirmesi Illumina'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$3b
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	US$5m	US$250k	-US$1b

Tazminat ve Piyasa: Jacob 'nin toplam tazminatı ($USD 4.69M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 13.04M ).

Tazminat ve Kazançlar: Jacob şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Jacob Thaysen (49 yo)

1.1yrs

Görev süresi

US$4,691,233

Tazminat

Mr. Jacob Thaysen, Ph.D. serves as Chief Executive Officer at Illumina, Inc. since September 25, 2023 and serves as its Director since September 2023. Mr. Thaysen joined the Illumina, Inc. in September 202...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jacob Thaysen	CEO & Director	1.1yrs	US$4.69m	0.0046% $ 1.0m
Carissa Rollins	Chief Information Officer	2.6yrs	US$2.93m	0.0011% $ 241.1k
Charles Dadswell	Senior VP & General Counsel	11.5yrs	US$4.10m	0.0044% $ 998.1k
Stephanie Campos	President	no data	Veri yok	Veri yok
Ankur Dhingra	Chief Financial Officer	no data	Veri yok	Veri yok
Kevin Pegels	Chief of Global Operations	2.9yrs	Veri yok	0.011% $ 2.4m
Scott Ericksen	VP & Chief Accounting Officer	2yrs	Veri yok	0.0067% $ 1.5m
Steven Barnard	Chief Technology Officer	1.2yrs	Veri yok	0.017% $ 3.9m
Sallilyn Schwartz	Vice President of Investor Relations	3.8yrs	Veri yok	Veri yok
Jakob Wedel	Chief Strategy & Corporate Development Officer and CEO Chief of Staff	less than a year	Veri yok	0.0044% $ 991.3k
Pat Leckman	Senior VP & Chief People Officer	less than a year	Veri yok	0.0055% $ 1.2m
Nicole Berry	Head of Region-Americas	no data	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: ILMN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jacob Thaysen	CEO & Director	1.1yrs	US$4.69m	0.0046% $ 1.0m
Caroline Dorsa	Independent Director	7.8yrs	US$408.88k	0.0062% $ 1.4m
Susan Siegel	Independent Director	5.7yrs	US$398.58k	0.0050% $ 1.1m
Stephen MacMillan	Independent Chairman of the Board	1.3yrs	US$388.22k	0.00095% $ 214.0k
Philip Schiller	Independent Director	8.3yrs	US$395.10k	0.0086% $ 1.9m
Robert Epstein	Independent Director	11.9yrs	US$405.10k	0.0098% $ 2.2m
Gary Guthart	Independent Director	6.8yrs	US$404.29k	0.0063% $ 1.4m
Scott Ullem	Independent Director	1.3yrs	US$345.03k	0.0013% $ 290.6k
Frances Arnold	Independent Director	8.8yrs	US$400.10k	0.0092% $ 2.1m
Leslie Biesecker	Member of Ethics Advisory Board	no data	Veri yok	Veri yok
Scott Gottlieb	Independent Director	4.7yrs	US$391.37k	0.0035% $ 788.5k
Clement Adebamowo	Member of Ethics Advisory Board	no data	Veri yok	Veri yok

6.3yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ILMN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).

Illumina Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Illumina, Inc. Announces Executive Changes

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Illumina, Inc. Announces Chief Financial Officer Changes

CEO & Director recently bought US$992k worth of stock

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Recent updates

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Consensus EPS estimates fall from profit to US$1.71 loss

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Consensus EPS estimates upgraded to US$0.93 loss

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Now 24% overvalued

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Now 22% overvalued

Illumina: Expect A Slow Rebound

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Consensus EPS estimates fall by 25%

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Consensus EPS estimates upgraded to US$0.56 loss

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

CEO & Director recently bought US$992k worth of stock

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Full year 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 20% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Price target decreased by 15% to US$168

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

Price target decreased by 9.4% to US$203

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Price target decreased by 7.0% to US$224

Second quarter 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023

The Big Trends: New Frontiers in Healthcare

Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt